Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

311
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
311
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

386
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
386
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

3.7K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
3.7K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

225
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
225
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

331
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
331
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

227
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
227

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Performance Multi-Walled Carbon Nanotubes-Organic Passivated Si Solar Cells Enabled by Spatially Selective Harvesting of High-Quality Sponges.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Sex specific modulation of LC neuronal activity in a binge drinking mouse model.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

Design, synthesis, and biological evaluation of 1H-1,2,4-triazole-3-carboxamides as apelin receptor agonists.

Bioorganic & medicinal chemistry letters·2026
Same author

Distinctive molecular architectures of G<sub>q</sub>- and G<sub>i</sub>-coupled GLP-1 receptors.

Acta pharmaceutica Sinica. B·2026
Same author

Structural insight into ligand binding and activation of the orphan GPCR Mas1.

The EMBO journal·2026
Same author

Passivating pinholes for large-area and high-efficiency silicon solar cells with tunnel oxide passivated contact.

Nature communications·2026

Related Experiment Video

Updated: Aug 23, 2025

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.6K

An emerging direction in glucagon-based therapy.

Yan Chen1, Dehua Yang2, Ming-Wei Wang3

  • 1Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.

Cell Metabolism
|November 2, 2022
PubMed
Summary

Vps37a protein regulates liver metabolism by controlling the glucagon receptor (GCGR). This finding offers a new therapeutic strategy for type 2 diabetes by uncoupling glucose and lipid metabolism.

More Related Videos

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

7.6K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

Related Experiment Videos

Last Updated: Aug 23, 2025

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.6K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

7.6K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

Area of Science:

  • Cellular metabolism
  • Endocrinology
  • Molecular biology

Background:

  • The glucagon receptor (GCGR) plays a critical role in regulating hepatic metabolism, particularly glucose production.
  • Dysregulation of hepatic metabolism is a hallmark of type 2 diabetes.
  • Understanding the precise control mechanisms of GCGR signaling is crucial for developing effective diabetes therapies.

Purpose of the Study:

  • To investigate the role of the endosomal protein Vps37a in regulating GCGR function.
  • To elucidate how Vps37a affects the intracellular localization and signaling of GCGR.
  • To explore the potential of targeting the Vps37a-GCGR interaction for type 2 diabetes treatment.

Main Methods:

  • Cellular assays to examine protein localization and interaction.
  • Biochemical analyses of GCGR signaling pathways.
  • In vivo studies to assess metabolic effects.

Main Results:

  • Vps37a was identified as a regulator of GCGR intracellular trafficking.
  • Vps37a alters the endosomal localization of GCGR, impacting its signaling.
  • This alteration uncouples hepatic glucose production from lipid metabolism.

Conclusions:

  • Vps37a is a novel regulator of GCGR, influencing hepatic glucose and lipid metabolism.
  • Targeting Vps37a-mediated GCGR localization presents a potential therapeutic avenue for type 2 diabetes.
  • Further research into this mechanism could lead to innovative diabetes management strategies.